Modal Title
Course Description
Depression is a global, widespread mental health disorder, affecting 350 million people. For some, current treatment modalities are not sufficient to support patient needs. This continuing education program will review and synthesize current evidence about the use of glutamate receptor modular medications (ketamine and esketamine) for treatment resistant depression. These medications have shown rapid and significant lifting of mood and suicidal ideation in symptomatic patients. An in-depth discussion of adverse effects, patient selection, treatment and administration protocols, and concerns for patient safety will be presented.
Intended Audience
- Physicians
- Nurses
- Advanced Practice Nurses
- Physicians Assistants
- Pharmacists
- Psychologists
- Other Allied Health
Learning Objectives
At the completion of this activity, healthcare providers will be able to:
- Explain the burden of depressive disorders as a chronic, relapsing condition, and their associated costs, morbidity, and mortality
- Provide a brief synopsis of the proposed mechanism of action, pharmacodynamics, and pharmacokinetics for glutamate receptor modulators to treat TRD and major depression with suicidal ideation
- Evaluate the efficacy of ketamine and esketamine to produce a meaningful response in individuals with TRD and major depression with suicidal ideation
- Interpret dosing regimens, with attention to the risks, benefits, costs, barriers, and burdens
- Summarize the incidence and management of adverse effects associated with the psychiatric use of ketamine/esketamine therapy
- Determine appropriate patient selection, setting, personnel, and monitoring for safe administration and security in a clinical setting
- Assess items from safety tools, such as the Risk Evaluation and Mitigation Strategy (REMS) in creating a safety net and best practices for administering ketamine and esketamine
- Outline the concerns over misuse and diversion of ketamine/esketamine
- Identify future research and clinical practice guideline directions needed to improve the wide-ranging concerns and implications for using ketamine and esketamine for TRD and major depression with suicidal ideation
Details
- Credit/Contact Hours
- 2.5
- Pharmacotherapy Hours
- 2.5
- Faculty
-
- Kathy Gardner, DNP, APRN, FNP-BC, CNM, CNE
Faculty, Frontier Nursing University
- Kathy Gardner, DNP, APRN, FNP-BC, CNM, CNE
- Language
-
- English
- Release Date
- February 1, 2023
- Expiration Date
- February 1, 2026
- Instructional Methods
-
- Assessment Review with Rationale
- Case Studies
- Ungraded Self Assessment-Lesson Recall
- Video Clips
- Video Narration
- Assessment
-
- Autograded and Quiz Retakes Allowed
- Daily CE Broker Reporting for Registered Boards
- Graded Final Quiz
- Passing 80%+
State/Local Approvals
- Approved/Accepted By
-
- Arkansas State Board of Nursing
- Bahamas Medical Council
- District of Columbia Board of Nursing
- Florida Board of Medicine
- Florida Board of Nursing
- Florida Board of Nursing - Certified Nursing Assistants
- Florida Board of Osteopathic Medicine
- Florida Board of Pharmacy
- Florida Council of Licensed Midwifery
- Florida Physician Assistants
- Georgia Board of Nursing
- Georgia Composite Medical Board - Physician Assistants
- Georgia Composite Medical Board - Physicians & Telemedicine
- Kansas State Board of Nursing
- Kentucky Board of Nursing
- Louisiana State Board of Medical Examiners - Medical Psychologist
- Louisiana State Board of Medical Examiners - Physicians & Surgeons
- Michigan Board of Nursing
- Michigan Board of Pharmacy
- Michigan Board of Psychology
- Mississippi Board of Nursing
- Mississippi State Board of Medical Licensure
- New Hampshire Medical Society
- New Mexico Board of Nursing
- New Mexico Certified Nurse Midwives and Licensed Midwives
- New Mexico Medical Board
- North Carolina Psychology Board
- Oklahoma Board of Medical Licensure and Supervision - Medical Doctors
- Oklahoma Board of Medical Licensure and Supervision - Physician Assistants
- South Carolina Board of Examiners in Psychology
- South Carolina Board of Medical Examiners
- South Carolina Board of Nursing
- South Carolina Board of Podiatry Examiners
- South Carolina Board of Examiners in Psychology
- State Medical Board of Ohio
- Tennessee Board of Examiners in Psychology
- Tennessee Board of Medical Examiners
- Tennessee Board of Osteopathic Examination
- West Virginia Board of Registered Nurses
- Wyoming Board of Nursing
- Wyoming Board of Psychology
CE Accreditation
- Accrediting CEs
-
Jointly provided by Partners for Advancing Clinical Education (PACE) and Premiere Education.
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Premiere Education. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.5 contact hour(s).
Designated for 2.5 contact hour(s) of pharmacotherapy credit for Advance Practice Registered Nurses.Physician Continuing Education
PACE designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacy Continuing Education
PACE designates this continuing education activity for 2.5 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-23-018-H01-P
Type of Activity: ApplicationUpon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Psychologist Continuing Education
Credit Designation
This program offers 2.5 continuing education credit(s) for psychologists. - Instructions for CE Credit
-
Participation in this self-study activity should be completed in approximately 2.5 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from February 1, 2023 through February 1, 2026:
- Review objectives and disclosures
- Study the educational content
- Successfully complete activity assessment(s)
- Complete the activity evaluation
You must receive an assessment score of at least 80% and respond to all evaluation questions to receive a certificate.
Disclosures
- Disclosures
-
Disclosure of Conflicts of Interest
PACE requires planners, faculty, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty: The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:
-
Kathy Gardner, DNP, APRN, FNP-BC, CNM, CNE
Faculty, Frontier Nursing University
• has no relevant financial relationships with ineligible companies to disclose
Planners & Managers & Translators: The PACE & Premiere Education planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
-
Kathy Gardner, DNP, APRN, FNP-BC, CNM, CNE